X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (36262) 36262
Newspaper Article (1137) 1137
Newsletter (400) 400
Magazine Article (226) 226
Book Chapter (100) 100
Trade Publication Article (24) 24
Transcript (19) 19
Book / eBook (12) 12
Book Review (11) 11
Publication (11) 11
Web Resource (11) 11
Dissertation (8) 8
Conference Proceeding (6) 6
Reference (4) 4
Government Document (2) 2
Report (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32030) 32030
female (16650) 16650
anticoagulants - adverse effects (16520) 16520
male (15940) 15940
anticoagulants (14514) 14514
anticoagulants - therapeutic use (13879) 13879
aged (12055) 12055
middle aged (11638) 11638
anticoagulants - administration & dosage (8372) 8372
risk factors (7716) 7716
adult (7368) 7368
warfarin (6515) 6515
treatment outcome (6314) 6314
cardiac & cardiovascular systems (5242) 5242
hemorrhage - chemically induced (5126) 5126
aged, 80 and over (4962) 4962
hematology (4575) 4575
thrombosis (4377) 4377
peripheral vascular disease (4294) 4294
warfarin - adverse effects (4270) 4270
surgery (4190) 4190
stroke (3987) 3987
thromboembolism (3960) 3960
retrospective studies (3944) 3944
prevention (3769) 3769
heparin - adverse effects (3765) 3765
atrial fibrillation (3647) 3647
anticoagulation (3482) 3482
risk (3447) 3447
administration, oral (3352) 3352
time factors (3300) 3300
medicine, general & internal (3223) 3223
heparin (3188) 3188
therapy (3166) 3166
management (2985) 2985
warfarin - therapeutic use (2985) 2985
pharmacology & pharmacy (2877) 2877
atrial fibrillation - drug therapy (2872) 2872
care and treatment (2822) 2822
venous thromboembolism (2794) 2794
mortality (2767) 2767
patients (2740) 2740
drug therapy (2638) 2638
abridged index medicus (2620) 2620
risk assessment (2551) 2551
heparin - therapeutic use (2508) 2508
prospective studies (2477) 2477
medicine & public health (2392) 2392
analysis (2381) 2381
international normalized ratio (2294) 2294
warfarin - administration & dosage (2255) 2255
thromboembolism - prevention & control (2249) 2249
molecular-weight heparin (2233) 2233
health aspects (2230) 2230
stroke - prevention & control (2222) 2222
aspirin (2197) 2197
hemorrhage (2168) 2168
dabigatran (2121) 2121
atrial fibrillation - complications (2057) 2057
thrombocytopenia - chemically induced (2054) 2054
follow-up studies (2045) 2045
bleeding (1975) 1975
rivaroxaban (1949) 1949
research (1920) 1920
adolescent (1913) 1913
platelet aggregation inhibitors - therapeutic use (1900) 1900
complications (1891) 1891
animals (1889) 1889
atrial-fibrillation (1878) 1878
cardiology (1873) 1873
incidence (1791) 1791
heparin - administration & dosage (1756) 1756
pregnancy (1755) 1755
cardiac arrhythmia (1725) 1725
anticoagulants - pharmacology (1700) 1700
blood coagulation - drug effects (1653) 1653
complications and side effects (1626) 1626
thrombosis - prevention & control (1586) 1586
platelet aggregation inhibitors - adverse effects (1549) 1549
safety (1548) 1548
dosage and administration (1542) 1542
thrombosis - etiology (1518) 1518
deep-vein thrombosis (1511) 1511
fibrinolytic agents - therapeutic use (1490) 1490
stroke - etiology (1487) 1487
clinical trials (1473) 1473
dose-response relationship, drug (1451) 1451
drug interactions (1441) 1441
heparin, low-molecular-weight - therapeutic use (1403) 1403
internal medicine (1391) 1391
thromboembolism - etiology (1383) 1383
risk-factors (1381) 1381
medical research (1365) 1365
drug therapy, combination (1346) 1346
venous thromboembolism - prevention & control (1344) 1344
recurrence (1331) 1331
diagnosis (1321) 1321
randomized controlled trials as topic (1302) 1302
studies (1298) 1298
usage (1280) 1280
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (9) 9
Gerstein Science - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Pharmacy (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Credit Valley Hospital - Closed Orders (1) 1
Scarborough Hospital - General (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (34482) 34482
German (1132) 1132
French (994) 994
Spanish (443) 443
Japanese (260) 260
Italian (190) 190
Russian (185) 185
Polish (93) 93
Swedish (92) 92
Dutch (89) 89
Danish (74) 74
Norwegian (66) 66
Hungarian (63) 63
Czech (62) 62
Portuguese (62) 62
Chinese (56) 56
Turkish (29) 29
Hebrew (23) 23
Romanian (19) 19
Finnish (18) 18
Croatian (15) 15
Serbian (13) 13
Bulgarian (10) 10
Korean (7) 7
Slovak (6) 6
Bosnian (3) 3
Lithuanian (3) 3
Ukrainian (3) 3
Arabic (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
.... In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
.... Risk ratios (RR) for VTE and bleed end-points were estimated using fixed and random effects meta-analysis... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | ENOXAPARIN | meta-analysis | RANDOMIZED-TRIAL | REPLACEMENT | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | THROMBOSIS PROPHYLAXIS | US HOSPITALS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | UNFRACTIONATED HEPARIN | REGISTRY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Clinical orthopaedics and related research, ISSN 1528-1132, 2008, Volume 466, Issue 3, pp. 714 - 721
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 12/2016, Volume 2016, Issue 12, p. CD008500
Background Venous thromboembolism (VTE) often complicates the clinical course of cancer. The risk is further increased by chemotherapy, but the trade‐off... 
Prevention: physical approaches | Medical prophylaxis | Physical methods of prophylaxis | Hemorrhage | Neoplasms | Prevention | Antithrombins | Venous Thromboembolism | Child health | Prevention: medical approaches | Heart & circulation | Thromboembolism | Anticoagulants | Warfarin | Mechanical prophylaxis | Antineoplastic Agents | Deep vein thrombosis | Heparin, Low‐Molecular‐Weight | Ambulatory Care | Randomized Controlled Trials as Topic | Vitamin K Antagonists | Pulmonary Embolism (PE) | Deep vein thrombosis (DVT) related | Pulmonary Embolism | Heparin | Medicine General & Introductory Medical Sciences | Hemorrhage [chemically induced] | Pulmonary Embolism [etiology; prevention & control] Randomized Controlled Trials as Topic | LOW-DOSE WARFARIN | Humans | Anticoagulants [adverse effects; therapeutic use] | RANDOMIZED-TRIAL | Antithrombins [therapeutic use] | Heparin [adverse effects; therapeutic use] | FACTOR-BEARING MICROPARTICLES | Heparin, Low-Molecular-Weight [adverse effects; therapeutic use] | Neoplasms [complications; drug therapy] | BLEEDING COMPLICATIONS | CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | Venous Thromboembolism [etiology; prevention & control] Warfarin [adverse effects; therapeutic use] | MOLECULAR-WEIGHT HEPARIN | METASTATIC BREAST-CANCER | Adult | Antineoplastic Agents [adverse effects] | PLACEBO-CONTROLLED TRIAL | Child | DEEP-VEIN-THROMBOSIS | Pulmonary Embolism - prevention & control | Antithrombins - therapeutic use | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Anticoagulants - therapeutic use | Heparin - therapeutic use | Anticoagulants - adverse effects | Heparin - adverse effects | Heparin, Low-Molecular-Weight - therapeutic use | Neoplasms - drug therapy | Venous Thromboembolism - etiology | Warfarin - therapeutic use | Neoplasms - complications | Venous Thromboembolism - prevention & control | Antineoplastic Agents - adverse effects | Pulmonary Embolism - etiology | Hemorrhage - chemically induced
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article